









Markets
/
Stocks
/
nasdaq-atai
/

ATAI Life Sciences NV

ATAI

3.770USD

+0.360+10.56%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

906.45MMarket Cap

LossP/E TTM



ATAI Life Sciences NV

3.770

+0.360+10.56%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of ATAI Life Sciences NV

Currency: USD Updated: 2026-02-06

Key Insights

ATAI Life Sciences NV's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 106 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.45.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ATAI Life Sciences NV's Score

Industry at a Glance

Industry Ranking

106 / 392

Overall Ranking

236 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

ATAI Life Sciences NV Highlights

StrengthsRisks

Atai Beckley NV, formerly ATAI Life Sciences NV, is a clinical-stage biopharmaceutical company. The Company focused on developing treatments for mental health disorders. The Company's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 32.19% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 308.00K.

Fairly Valued

The company’s latest PE is -4.56, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 45.07M shares, increasing 0.04% quarter-over-quarter.

Held by Catherine Wood

Star Investor Catherine Wood holds 2.02M shares of this stock.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

12.455

Target Price

+245.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of ATAI Life Sciences NV is 6.81, ranking 208 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 749.00K, representing a year-over-year increase of 1772.50%, while its net profit experienced a year-over-year increase of 132.34%.

Score

Industry at a Glance

Previous score

6.81

Change



Financials

6.05

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.32

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.12

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.54

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

ATAI Life Sciences NV's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of ATAI Life Sciences NV is 6.35, ranking 291 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -4.56, which is -73.77% below the recent high of -1.20 and -173.33% above the recent low of -12.46.

Score

Industry at a Glance

Previous score

6.35

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 106/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of ATAI Life Sciences NV is 8.46, ranking 116 out of 392 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 16.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

8.46

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

12.455

Target Price

+245.00%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

ATAI Life Sciences NV

ATAI

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of ATAI Life Sciences NV is 7.49, ranking 67 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.19 and the support level at 3.34, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.75

Change

0.74

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.026

Sell

RSI(14)

47.258

Neutral

STOCH(KDJ)(9,3,3)

42.296

Buy

ATR(14)

0.248

Low Volatility

CCI(14)

-91.393

Neutral

Williams %R

47.053

Neutral

TRIX(12,20)

-0.253

Sell

StochRSI(14)

97.214

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

3.700

Buy

MA10

3.777

Sell

MA20

3.795

Sell

MA50

3.973

Sell

MA100

4.537

Sell

MA200

3.742

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of ATAI Life Sciences NV is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 10.88%, representing a quarter-over-quarter decrease of 44.34%. The largest institutional shareholder is Catherine Wood, holding a total of 2.02M shares, representing 0.56% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Apeiron Investment Group Ltd

55.21M

+0.03%

Feilding-Mellen (Cosmo)

7.70M

Adage Capital Management, L.P.

5.43M

Brand (Florian Olaf)

5.04M

-4.73%

Morgan Stanley Investment Management Inc. (US)

3.23M

+75.10%

Citadel Advisors LLC

2.58M

+118.39%

Ally Bridge Group NY LLC

2.29M

BlackRock Institutional Trust Company, N.A.

2.18M

+2973.34%

Candriam Luxembourg S.A.

1.72M

ARK Investment Management LLC

Star Investors

2.02M

+29.31%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of ATAI Life Sciences NV is 4.10, ranking 108 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.62. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.